Capping Prescription Costs Act of 2025
- Bill Number
- S. 529
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-02-11: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-02-04T05:06:14Z
AI-Generated Summary
Purpose
The "Capping Prescription Costs Act of 2025" aims to reduce financial burdens on individuals and families by limiting out-of-pocket cost-sharing (the portion of prescription drug costs paid by the insured, such as copays or deductibles) for covered prescription drugs under certain health plans. It seeks to make medications more affordable, particularly for those with high drug expenses.
Key Provisions
- Cap on Costs for Qualified Health Plans: Amends the Affordable Care Act (ACA) to set annual limits on prescription drug cost-sharing:
- For 2026: $2,000 per individual or $4,000 per family.
- For 2027 and later: These amounts increase annually based on the medical care component of the Consumer Price Index (CPI) for urban consumers, published by the Bureau of Labor Statistics. Increases are rounded down to the nearest $5 if not a multiple of $5.
- Application to Group Health Plans: Adds requirements to three major laws:
- Public Health Service Act: Insurers offering group coverage must comply with the ACA caps.
- Employee Retirement Income Security Act (ERISA): Employer-sponsored plans must adhere to the same limits.
- Internal Revenue Code: Self-insured group plans (regulated under tax law) must follow the caps.
- Scope: Applies only to cost-sharing for prescription drugs covered by the plan; does not affect premiums or non-drug costs.
- Effective Date: Takes effect for plan years beginning on or after January 1, 2026.
Significant Changes to Existing Law
- Introduces the first federal cap specifically on prescription drug cost-sharing across ACA marketplace plans, employer group plans, and self-insured plans.
- Previously, while the ACA limited overall out-of-pocket maximums (e.g., $9,450 for individuals in 2024), there was no targeted limit just for prescription drugs, allowing high costs for expensive medications to exceed general caps in some cases.
- Harmonizes rules across federal health laws (ACA, ERISA, tax code) to ensure consistent application without creating loopholes for different plan types.
Potential Impacts
- On Citizens: Could save insured individuals and families thousands annually on high-cost drugs (e.g., for chronic conditions like cancer or diabetes), improving access to care and reducing medical debt. Low- and middle-income households may benefit most, though those without insurance remain unaffected.
- On Government Agencies: The Department of Health and Human Services (HHS), Department of Labor (DOL), and Internal Revenue Service (IRS) will need to update regulations, guidance, and enforcement to implement and monitor compliance, potentially increasing administrative workload.
- On Health Insurers and Employers: Insurers may face higher claims payouts, possibly leading to adjusted premiums or benefit designs. Employers offering group plans could see indirect costs but also healthier workforces with fewer absences due to untreated conditions.
- International Relations: Minimal direct impact, though it may influence U.S. drug pricing negotiations indirectly by pressuring pharmaceutical companies, which operate globally.
Main Stakeholders Affected
- Individuals and Families: Primary beneficiaries, especially those with chronic illnesses requiring ongoing prescriptions.
- Health Insurers: Must redesign plans to meet caps, affecting profitability and product offerings.
- Employers: Sponsors of group plans will need to ensure compliance, potentially altering employee benefits.
- Pharmaceutical Companies: Indirectly impacted as lower patient costs could increase drug utilization, but may prompt negotiations on pricing with insurers.
- Healthcare Providers: Pharmacies and doctors may see smoother prescription fulfillment, reducing barriers to treatment.
Notable Legal, Constitutional, or Political Implications
- Legal: Strengthens ACA protections by filling a gap in drug affordability; enforceable through existing federal oversight mechanisms, with potential for civil penalties for non-compliance under ERISA or tax rules. No challenges to plan coverage decisions are altered.
- Constitutional: Aligns with Congress's authority to regulate interstate commerce and health insurance markets; unlikely to raise federalism issues as it builds on established ACA framework without mandating state actions.
- Political: Represents a targeted expansion of consumer protections in healthcare, potentially appealing across party lines for affordability but facing opposition from those concerned about rising insurance premiums or industry burdens. As an amendment to multiple laws, it requires coordination in a divided Congress for passage.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Sen. Warnock, Raphael G. [D-GA]
Cosponsors (13)
Sen. Baldwin, Tammy [D-WI], Sen. Booker, Cory A. [D-NJ], Sen. Blumenthal, Richard [D-CT], Sen. Fetterman, John [D-PA], Sen. Gillibrand, Kirsten E. [D-NY], Sen. Heinrich, Martin [D-NM], Sen. Kim, Andy [D-NJ], Sen. Klobuchar, Amy [D-MN], Sen. Murray, Patty [D-WA], Sen. Welch, Peter [D-VT], Sen. Alsobrooks, Angela D. [D-MD], Sen. Lujan, Ben Ray [D-NM], Sen. Gallego, Ruben [D-AZ]
Recent Actions
- 2025-02-11: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-02-11: Introduced in Senate
Bill Versions
- Capping Prescription Costs Act of 2025 — issued 2025-02-11 — PDF (5 pages)